LBP-25-a phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b (chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study

2019 ◽  
Vol 70 (1) ◽  
pp. e153-e154 ◽  
Author(s):  
Yue Hu ◽  
Xiaomin WANG ◽  
zhiming wang ◽  
dong gao ◽  
lan zhang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Dose Escalation ◽  
Phase 1 ◽  
Therapeutic Vaccine ◽  
Dose Escalation Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Phase 1 Clinical Trial

scholarly journals Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

2020 ◽  
Vol 20 (4) ◽  
pp. 455-466 ◽  
Author(s):  
David K Clarke ◽  
Rong Xu ◽  
Demetrius Matassov ◽  
Theresa E Latham ◽  
Ayuko Ota-Setlik ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Virus Vaccine ◽  
Ebola Virus ◽  
Phase 1 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Phase 1 Clinical Trial

scholarly journals A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Blood ◽  
2016 ◽  
Vol 127 (4) ◽  
pp. 411-419 ◽  
Author(s):  
Harriet S. Walter ◽  
Simon A. Rule ◽  
Martin J. S. Dyer ◽  
Lionel Karlin ◽  
Ceri Jones ◽  
...  
Keyword(s):  
Clinical Trial ◽  
B Cell ◽  
Dose Escalation ◽  
Phase 1 ◽  
B Cell Malignancies ◽  
Dose Escalation Study ◽  
Phase 1 Clinical Trial ◽  
Human Dose ◽  
Key Points ◽  
Btk Inhibitor

Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

Sign in / Sign up

Export Citation Format

Share Document